Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Business Wire•03/11/2026•08:00 ET
0
Key Highlights
- ➤Stoke Therapeutics (STOK) schedules presentations at two November investor conferences
- ➤Zorevunersen is currently being evaluated in a Phase 3 Dravet syndrome study
- ➤Biogen (BIIB) holds exclusive rest-of-world commercialization rights for zorevunersen
- ➤Zorevunersen has received FDA and EMA orphan drug designation
- ➤FDA granted zorevunersen Breakthrough Therapy and rare pediatric disease designations
Expert Statements
Ian F. Smith, Chief Executive Officer of Stoke Therapeutics
“Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences:”
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investor conferences:
Get started
Create a free account to read the full story.